FDA-approved drugs like oxypertine, pemigatinib, selpercatinib, and belumosudil showed encouraging results with high binding affinities and can be further explored for their inhibitory effects on ILK and treating high-grade meningioma. The gene discussed is ILK; the disease is meningioma.